After being knocked down for the count in the first quarter of the year, the biopharma sector got off the canvas to post significant gains in April. The industry will be looking to maintain that renewed investor interest as its blue chip companies report their first quarter financial results. Strong earnings results and a positive outlook for the rest of 2016 will go a long way to counteract the negative sentiment, which continues to swirl around drug developers generated by the drug price "gouging" debate.